← SynDRA
OPROZOMIB
SynDRA canonical compound SYN0030082 — structure-anchored drug synonym record
| Clinical phase | Phase 1/Phase 2 |
|---|
| Mechanism of action | proteasome inhibitor |
|---|
All known targets
- PSMB5
- ADRM1
- PSMD12
- PSMC3
- PSMC4
- PSMC5
- PSMC6
- PSMD1
- PSMD11
- PSMD13
- PSMC1
- PSMD14
Mechanisms of action (all sources)
- PSMD1 INHIBITOR
- proteasome inhibitor
- PSMB2 INHIBITOR
- PSMB1 INHIBITOR
- PSMB5 INHIBITOR
- PSMB8 INHIBITOR
- PSMB9 INHIBITOR
- PSMB6 INHIBITOR
- PSMD14 INHIBITOR
- PSMA1 INHIBITOR
- PSMA2 INHIBITOR
- PSMA3 INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ABCB5
- ATXN2
- HLAB
- HTT
- IFNB1
- KSYK
- MDR1
- MITF
- NSD2
- PARP1
- SYK
- TFE3
- TP53
Cross-references
Synonyms
- Pr-047
- ONX-0912
- ONX 0912
- PR 047
- Oprozomib (ONX 0912)
- N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide
- MZ37792Y8J
- O-Methyl-N-((2-methylthiazol-5-yl)carbonyl)-L-seryl-O-methyl-N-((1S)-1-benzyl-2-((2R)- 2-methyloxiran-2-yl)-2-oxoethyl)-L-serinamide
- N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
- Oprozomib [USAN]
- Oprozomib [USAN:INN]
- UNII-MZ37792Y8J
- Onx0912(oprozomib)
- OPROZOMIB [INN]
- Oprozomib (USAN/INN)
- OPROZOMIB [WHO-DD]
- GTPL8739
- SCHEMBL1709971
- CHEMBL2103884
- EX-A332
- DTXSID201025950
- BCP07603
- BDBM50398607
- MFCD25976563
- NSC766254
- ZINC43202141
- AKOS028109171
- DB11991
- NSC-766254
- NCGC00345799-01
- NCGC00345799-02
- NCGC00345799-04
- AS-17020
- HY-12113
- L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-
- A14181
- D10318
- J-690398
- Q27088209
Look up OPROZOMIB in the interactive SynDRA portal →